• Adjusted EBITDA (Q4 2024): $532 million, a 6% year-over-year improvement.
• Adjusted EBITDA Margin (Q4 2024): 28%, a 50 basis point year-over-year improvement.
• Adjusted Earnings Per Share (Q4 2024): $0.84.
• Adjusted Earnings Per Share (Full Year 2024): $3.29, up 11% year-over-year.
• Free Cash Flow (Q4 2024): $491 million, with a 26% free cash flow margin.
• Total Liquidity (End of Q4 2024): $4.1 billion, including $1.5 billion of cash on hand.
• Revenue Growth (Q4 2024): Increased by 4% year-over-year.
• Orders Growth (Q4 2024): Up 8% year-over-year.
• Book-to-Bill Ratio (Q4 2024): 0.95.
• Adjusted EBITDA Margin (Full Year 2024): 27.9%, up 190 basis points from the prior year.
• Corporate Costs (Q4 2024): $32 million, down $15 million year-over-year.
• Leverage (End of Q4 2024): 1.6 turns, a one turn increase year-over-year.
• ITS Segment Adjusted EBITDA Margin (Full Year 2024): 30.2%.
• PST Segment Adjusted EBITDA (Q4 2024): $107 million, with a margin of 27.6%.
• 2025 Revenue Growth Guidance: Expected to grow between 3% and 5%.
• 2025 Adjusted EPS Guidance: Projected to be between $3.38 and $3.50.

• Warning! GuruFocus has detected 3 Warning Sign with IR.

Release Date: February 14, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

• Ingersoll Rand Inc (NYSE:IR) achieved double-digit adjusted EPS growth and strong free cash flow margin in 2024 despite a dynamic global market.
• The company has a robust M&A strategy with over 200 active targets, aiming for 400 to 500 basis points of annualized inorganic revenue growth in 2025.
• Ingersoll Rand Inc (NYSE:IR) was named to the Dow Jones Best-in-class Indices for the third consecutive year, ranking number one in its industry.
• The company has created approximately $700 million of incremental wealth for its employees through ownership equity grants.
• Ingersoll Rand Inc (NYSE:IR) delivered a near-record adjusted EBITDA margin of 28% in Q4 2024, driven by gross margin expansion.

Negative Points

• The company experienced lower volumes in its Aerospace & Defense business, impacting PST margins.
• Organic revenue growth in the first half of 2025 is expected to be flat, with only a modest improvement in the second half.
• China's market performance was softer than anticipated, affecting overall company organic order growth.
• The PST segment faced challenges with lower volumes and organic volume declines, particularly in China.
• There is uncertainty around the impact of potential tariffs and geopolitical dynamics on future operations.

Q & A Highlights

Q: Can you discuss the assumptions embedded in the guidance from a demand perspective and how you see the orders playing out this year? A: Vicente Reynal, CEO, explained that the revenue phasing is expected to be consistent with historical patterns. Organic growth is anticipated to be flat in the first half of the year, with approximately 4% growth in the second half. This growth is driven by pricing and volume, with a focus on unpenetrated regions and new product development. The regional growth assumptions include upper-end low single digits for America, lower-end low single digits for mainland Europe, flat for China, and mid-single digits for the Middle East, India, and the rest of Asia.

Q: Can you elaborate on the PST margins in the quarter and how they are expected to ramp through the next year? A: Vikram Kini, CFO, noted that the lower margins were due to decreased volumes in the ILC Dover Aerospace and Defense business and organic volume declines, primarily from China. However, they remain optimistic about achieving mid-30s EBITDA margins over time, driven by price-cost positivity, productivity improvements, restructuring, and integration activities. They expect to return to a 30% EBITDA margin profile as they progress through 2025.

Q: How did orders perform in Q4, and what are the expectations for Q1? A: Vicente Reynal stated that Q4 orders were primarily impacted by China, with organic order growth essentially flat. However, excluding China, orders were up low single digits. For Q1, they expect organic revenue growth to be down low single digits, with orders expected to be around one on a full-year basis, consistent with historical seasonality.

Q: What is the outlook for the ILC Dover business, particularly in Life Sciences and Aerospace & Defense? A: Vicente Reynal highlighted that ILC Dover's Life Sciences business continues to perform well, with double-digit revenue growth. They are seeing good cross-selling opportunities and revenue synergies, particularly with large medical device customers. The Aerospace & Defense business is seen as optional, with no current M&A plans in that area.

Q: How is the M&A strategy expected to impact growth, and what is the focus for 2025? A: Vicente Reynal mentioned that they have a strong M&A funnel with over 200 companies and expect to acquire an additional 400 to 500 basis points of annualized inorganic revenue in 2025. The focus is on bolt-on acquisitions that expand capabilities in high-growth sustainable markets, with a disciplined approach to ensure shareholder value.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.